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THE INFLUENCE OF DAPAGLIFLOZIN ON DIETARY MEDIATED PHYSIOLOGICAL 
AND BEHAVIORAL CHANGES 
 
 
The diabetes medication, Dapagliflozin, is a sodium-glucose co-transporter 2 (SGLT2) 
inhibitor. The mechanism of action is decreasing renal absorption of glucose, leading to 
glucosuria, and modest weight loss. We hypothesized that SGLT2 inhibition would potentiate the 
favorable influence of dietary counseling on body composition and physiological adaptations in 
overweight or obese adults. Fifty sedentary overweight/obese men (n = 12) and women (n = 38) 
were randomly assigned to 12 weeks of dietary counseling for weight loss, supplemented with 
daily ingestion of either placebo or Dapagliflozin (up to 10 mg/day); coded as Pill A and Pill B. 
Dietary counseling consisted of weekly, one-on-one, 30-minute meetings targeting modest 
calorie restriction. Before and after treatment, body composition, resting metabolic rate (RMR), 
insulin sensitivity, appetite and satiety were measured. Twelve weeks of dietary counseling 
decreased (P < 0.049) body mass, fat mass, and RMR; neither variable was influenced by pill 
assignment (interaction: P > 0.264). Dietary counseling also decreased lean mass (treatment 
main effect: P < 0.001), however the decrease in lean mass was greater in Pill B than in Pill A 
(interaction: P = 0.037).  Neither dietary counseling nor SGLT2 inhibition influenced insulin 
sensitivity (P > 0.055). Overall, 12-weeks of dietary counseling leads to favorable modification 
of body mass and fat mass regardless of pill assignment. However, Pill A appears to reduce the 
dietary counseling mediated loss in lean mass. Except for lean mass, the effects of dietary 
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In the 45 minutes it takes to read this review 387 people in the United States will be 
diagnosed with Type-2-Diabetes (T2D). With over 415 million adults worldwide and 30.3 
million people in the U.S.A. currently diagnosed with T2D (Ogurtsova et al., ADA, 2017), 
immediate curable and preventable action is required. 
T2D results from a cocktail of behavioral and environmental risk factors, combined with 
genetic predisposition (Hamman, 1992; Neel, 1962; Ohlson et al., 1988; Tuomilehto et al., 
2001). While the genetic foundation of T2D is yet to be fully described, there is overwhelming 
evidence that physical inactivity and obesity are major determinants (King et al., 1990; 
Lindström et al., 2003; Manson et al., 1991). 
Clinically, T2D is diagnosed based on a fasting blood glucose concentration greater than 
125 mg/dl (6.9 mmol/L). However, recently, a conservative approach is being adopted and 
people with pre-diabetes, characterized by a fasting blood glucose concentration between 100-
125 mg/dl (5.6-6.9 mmol/L), are recommended to begin preventative pharmaceutical treatment 
and/or lifestyle changes. The progression toward T2D is associated with high plasma insulin due 
to insulin resistance developing in insulin responsive tissues. Insulin resistance results in chronic 
hyperglycemia followed by numerous late stage T2D complications including: decreased insulin 
secretion (pancreatic β-cell failure), accelerated lipolysis, dyslipidemia, incretin resistance 
(gastrointestinal tract), glycation of blood brain barrier (insulin resistance/leptin resistance) 
hyperglucagonemia, and increased renal glucose reabsorption (Florez, 2008; Fonseca, 2009; 
Hoerger et al., 2008; McCarthy, 2010; Wilding et al., 2014).  
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  Unfortunately, the chronic hyperglycemia in T2D creates an environment that promotes  
protein glycation, covalent bonds between glucose and plasma proteins (Singh et al., 2014). 
Long term complications of advanced glycation end products include retinopathy, neuropathy, 
and cardiomyopathy (Ahmad et al., 2016; Donahoe et al., 2007; Ritz & Orth, 1999; Roger et al., 
2011; Singh et al., 2014). Hence, patients must make lifestyle and/or pharmaceutical changes to 
prevent T2D symptom progression. Lifestyle regulates diabetes. Some beneficial lifestyle 
changes include, exercise and a low-calorie, low refined sugar, high fiber diet (Bhatt et al., 2017; 
Schwingshackl et al., 2017), and more recently a low carbohydrate, higher fat diet.  
The American College of Sports Medicine (ACSM) has recommended 150 minutes of 
moderate aerobic exercise per week for diabetes prevention. However, recent studies support the 
efficacy of low-volume high-intensity interval training (HIIT) (Gibala et al., 2012; Little et al., 
2011) and resistance exercise to improve glycemic control (Richards et al., 2010; van Dijk et al., 
2012). While, in theory, regular exercise is beneficial for patients with T2D, there are numerous 
person limitations; these include poor habitual compliance due to the perceived time 
commitment, insufficient knowledge of proper exercise techniques, and the financial burden of 
equipment and gym membership. Pharmaceuticals provide an alternative option for 
hyperglycemia treatment. However, despite the reasonable success of current anti-diabetes drugs, 
side effects and complications exist (Opie et al., 2011).  
One of the earlier pharmaceutical therapies was Metformin. This medication is arguably 
the most commonly prescribed treatment for diabetes and has been recommended as the first 
course of action by the American Diabetes Association (ADA). Metformin lowers hepatic 
gluconeogenesis (He et al., 2009; Hundal et al., 2000; Madiraju et al., 2014), decreases gastro-
intestinal glucose absorption (Wu et al., 2017), and improves insulin sensitivity (Patanè et al., 
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2000). However, the use of metformin has unfavorable side effects (DeFronzo et al., 2016). 
Additionally, not all patients with T2D tolerate Metformin supplementation (Rosenstock et al., 
2017). If oral Metformin fails, insulin therapy is often supplemented as another pharmacological 
intervention for hyperglycemia (Inzucchi et al., 2014; Kilov et al., 2013). However, due to 
increasing insulin resistance, patients with T2D receiving insulin therapy, often require increased 
dosage. Higher insulin doses potentially lead to negative side effects including weight gain, fluid 
retention, and hypoglycemic events (Rosenstock et al., 2012; Stenlöf et al., 2013). Thus, there is 
a clear need for pharmacological therapy that will reverse hyperglycemia and prevent weight 
gain. In this regard, interest in a class of insulin independent drugs, sodium glucose cotransporter 
2 (SGLT2) inhibitors, has flourished.  
SGLT Proteins and Glucose Transport 
Recent research has emphasized the importance of the kidney in glucose homeostasis. 
The kidneys filter approximately 160-180 grams of glucose per day (Gerich, 2010). Healthy 
individuals reabsorb almost all glucose that flows through the glomeruli. If glucose 
concentrations are too high, then the excess is not reabsorbed but rather excreted from the body 
via urine (glucosuria). The reabsorption of glucose is mediated by sodium glucose co-transporter 
(SGLT) proteins in an insulin independent process (Okabe et al., 2003). 
Sodium glucose co-transporters couple the transfer of glucose against the concentration 
gradient with sodium along the concentration gradient (Chen et al., 2013; Mackenzie et al., 
1996). There are three main SGLT proteins: SGLT1, SGLT2, and SGLT3. SGLT1 proteins are 
in the kidney and intestine and have a high affinity but low capacity to transport glucose. SGLT2 
proteins are in the kidney and pancreas and, in contrast to SGLT1, have a low affinity but high 
capacity for sodium glucose transport. SGLT3 proteins are found in the small intestine and 
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skeletal muscle and have a moderate affinity for glucose to transport (Zhao et al., 2007). The 
focus of this review is specifically on the SGLT2 proteins.  
The SGLT2 is in the proximal convoluted tubule of the kidney. Approximately ninety 
percent of the filtered glucose is reabsorbed from the kidney by SGLT2. The remaining ten 
percent is reabsorbed by SGLT1 in the distal portion of the proximal straight tubule (Kanai et al., 
1994; Wright et al., 2011). A reduction in SGLT2 expression caused by either mutation or 
inhibition leads to glucosuria (Kanai et al., 1994). Therefore, SGLT2 inhibition provides a 
potential mechanism for reversing hyperglycemia and enhancing weight loss.  
One important characteristic of SGLT2 proteins is that they are insulin independent. This 
is very different from the major glucose transport protein (GLUT4) in insulin-sensitive tissues, 
such as skeletal muscle and adipose tissue (Wright et al., 2011). Unlike GLUT4, SGLT2 proteins 
are membrane-bound proteins that actively transport glucose across the concentration gradient 
(Chen et al., 2013; Mackenzie et al., 1996; Wright et al., 2011). Additionally, because SGLT2 
proteins are non-insulin dependent, they are a potentially effective therapeutic target in a disease 
in which insulin action/production is damaged. 
SGLT2 Inhibition  
 Compared with metabolically health individuals, people with diabetes have elevated renal 
gluconeogenesis and glucose release (Gerich, 2010; Meyer et al., 1998; Meyer et al., 2004; 
Wilding et al., 2014). Hyperglycemia also occurs without the expected increase in glucosuria due 
to increased SGLT2 expression (Tabatabai et al., 2009). Expression of SGLT2 proteins increases 
transport maximum (absolute capacity of the kidneys to reabsorb glucose) approximately twenty 
percent higher in individuals with diabetes compared to their healthy counterparts (Mogensen, 
1971). This increased expression of SGLT2 protein raises the renal threshold for glucose 
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excretion (RTg) (Figure 1) (Liang et al., 2012; Rave et al., 2006; Ruhnau et al., 1997; Tabatabai 
et al., 2009; Wilding et al., 2014). In opposition, SGLT2 inhibition lowers RTg. (DeFronzo et al., 
2013).  
 While it is important for healthy individuals to reuptake glucose for energy use and 
storage, this increased RTg is maladaptive in patients with T2D and T1D (Abdul-Ghani et al., 
2011; Nauck, 2014). In a person with diabetes, the reabsorption of glucose will lead to elevated 
blood glucose levels and contribute to hyperglycemia, glucose toxicity, and β-cell damage 
caused by lasting exposure to elevated glucose concentrations (Robertson et al., 2003).  
Because of the maladaptive increased RTg caused by elevated SGLT2 expression, SGLT2 
inhibition is emerging as a novel treatment for patients with T2D. Ideally, SGLT2 inhibition will 
increase urinary glucose disposal (glucosuria). Augmented glucosuria reduces fasting plasma 
glucose, improves glucose tolerance leading to reduced glucose toxicity (decreased chronic 
hyperglycemia), promotes calorie loss that can promote, weight loss, and finally improves β-cell 
function and insulin sensitivity (Chen et al., 2013; Idris et al., 2009). 
Figure 1: Wilding et al. 2014 - Linear Relationship between UGE and Plasma 
Glucose Concentration  
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Influence of Dapagliflozin on Weight Loss and Metabolic Health 
Dapagliflozin is one of several SGLT2 inhibitors. As of 2012 in Europe and 2014 in the 
United States, dapagliflozin is approved for treatment of T2D. Following ingestion, the 
concentration of dapagliflozin peaks in plasma at two hours and has a half-life of fourteen hours 
(Obermeier et al., 2010). The pharmacokinetics of dapagliflozin in patients with T2D and in 
healthy participants are comparable (Komoroski, Vachharajani, Feng, et al., 2009). The 
recommended starting dosage of dapagliflozin is 5 mg/day, and increases to 10 mg /day in 
patients able to tolerate the higher dose or who require additional glycemic control.  
The Effect of Dapagliflozin on Weight Loss 
Weight gain is a common result of some diabetic medications such as thiazolidinediones 
(Fonseca, 2003). Numerous studies have observed weight loss in patients with T2D using 
dapagliflozin monotherapy (Bailey et al., 2012; Ferrannini et al., 2010; Kaku et al., 2013; 
Merovci et al., 2014). By inhibiting SGLT2 proteins and decreasing reabsorption and enhancing 
glucosuria, substantial calories (glucose) should be lost in the urine. In theory, this effect may 
lead to cumulative loss of calories, which should result in weight loss. Dapagliflozin induced 
glucosuria in diabetic patients leads to a net caloric loss of up to 200-300 kcal/day (List et al., 
2009).  
However, Dapagliflozin induced weight loss appears to plateau approximately one year 
after initiation of treatment (Wilding et al., 2012). This plateau might be explained, in part, by a 
decrease in resting metabolic rate (Frey-Hewitt et al., 1990)The implication for the patient 
wishing to maintain weight loss is that to continue to sustain negative energy balance caloric 
intake must be decreased and/or energy expenditure must be increased. 
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 Administration of dapagliflozin over 24-102 weeks has been reported to decrease total 
body mass, fat mass, visceral adipose tissue, subcutaneous adipose tissue, waist circumference, 
and the concentration of glycated hemoglobin (hemoglobin A1C), and improve glycemic control 
in patients with T2D (Bolinder et al., 2012; Wilding et al., 2012). Additionally, Dapagliflozin 
supplementation stabilizes insulin dosing (less volatile blood glucose concentrations) (Wilding et 
al., 2012). Furthermore, long-term observations indicate that sustained weight loss occurs with 
major decreases in mean arterial pressure and death due to cardiovascular events and stroke. 
These beneficial effects continue for up to two years without any increased rate of hypoglycemia 
(Bolinder et al., 2012; Wilding et al., 2012). 
Noteworthy, much of the dapagliflozin induced weight loss can be attributed to loss of fat 
mass (Bolinder et al., 2012). Excess adipose tissue is associated with ectopic lipid accumulation 
resulting in lipotoxicity, the damaging effects of excess fat accumulation on glucose metabolism 
(DeFronzo, 2010; Unger, 2003). Lipotoxicity partially mediates insulin resistance by 
phosphorylating the serine residue on IRS-1, inhibiting GLUT4 translocation and halting insulin 
dependent glucose uptake into cells. Additionally, lipotoxicity initiates increased release of 
inflammatory cytokines (TNF alpha and IL6). Therefore, by decreasing fat mass through SGLT2 
inhibition, dapagliflozin could, in theory, reverse lipotoxicity and potentially restore insulin 
sensitivity while lowering inflammation (Katsiki et al., 2010; Tang et al., 2017).  
Numerous studies have investigated dapagliflozin use by healthy diabetes-free adults; 
namely, pharmacokinetic characteristics (Komoroski, Vachharajani, Feng, et al., 2009; Yang et 
al., 2013), influence on appetite (Bertran et al., 2018), and co-administration with regular 
exercise (Newman et al., 2018). However, no study has specifically tested the influence of short-
term dapagliflozin on weight loss in overweight/obese, but otherwise healthy adults.  
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Other Effects of Dapagliflozin on Metabolic Function 
The Effect of Dapagliflozin on β-Cell Function 
Dapagliflozin reduces transport maximum of glucose by fifty-five percent (DeFronzo et 
al., 2013). Thus, dapagliflozin lowers RTg to levels below fasting glucose levels. Therefore, 
glucosuria occurs at lower glucose concentrations after SGLT inhibition in both patients with 
T2D and their healthy counterparts (DeFronzo et al., 2013). Increased glucosuria leads to 
improvements in β-cell function (Merovci et al., 2015; Solomon et al., 2012). 
Insulin resistance, lipotoxicity, and chronic elevation of plasma glucose, are just a few of 
the factors that contribute to β-cell dysfunction. For example, in normal glucose-tolerant 
individuals a small elevation in 24-hour plasma glucose concentration can lead to a twenty-four 
percent decrease in β-cell function (Solomon et al., 2012). Alternatively, lowering plasma 
glucose concentration with insulin therapy in T2D improves insulin secretion, reflective of 
properly functioning β-cells (Mayorov et al., 2005; Scarlett et al., 1982). Specifically, two weeks 
of glucose administration followed by dapagliflozin supplementation lowered blood glucose 
concentrations and improved β-cell function (Merovci et al., 2015). Thus, circulating glucose 
concentration influences β-cell function, based on evidence of the inverse association of 
prolonged glucose concentration and β-cell function. 
The Effect of Dapagliflozin on Pancreatic Alpha-Cells 
Dapagliflozin improves skeletal muscle insulin sensitivity but enhances endogenous 
glucose production independent of any decrease in plasma glucose concentration due to elevated 
plasma glucagon concentration (Merovci et al., 2015). It is currently believed that the elevated 
endogenous glucose production is due to inhibition of SGLT2 proteins expressed in the 
glucagon-secreting alpha-cells of the pancreatic islets (Bonner et al., 2015). Therefore, 
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dapagliflozin instigates glucagon secretion and enhanced endogenous (hepatic) glucose 
production. However, the glucose production is modest. For example, 10 mg/day of 
dapagliflozin increased circulating glucagon concentrations by 91% but had no effect of 
circulating blood glucose concentrations (Bonner et al., 2015). This direct effect of SGLT2 
inhibition on alpha-cells may counter the hyperglycemia lowering abilities of dapagliflozin.  
Effects of Dapagliflozin on Blood Pressure 
In addition to the maintenance of fluid and electrolyte homeostasis, the kidneys also 
regulate blood pressure. In healthy individuals, kidneys increase excretion of salt and water as 
blood pressure increases; consequently, lowering blood volume and blood pressure back to 
baseline (Oliva et al., 2014). Hypertension is another negative outcome of T2D. Over seventy-
five percent of adults with diabetes are either using antihypertensive drugs or have systolic blood 
pressures (SBP) greater than 140 mmHg (Proctor 2019).  
Data from a recent meta-analysis demonstrated that SGLT2 inhibitors reduce mean 
arterial blood pressure due to enhanced sodium excretion in patients with T2D (Baker et al., 
2014; Oliva & Bakris, 2014; Tikkanen et al., 2015), suggesting that SGLT2 inhibition not only 
improves glycemic control but also has a diuretic-like ability to lower BP (Lambers Heerspink et 
al., 2013). In rodent models, evidence suggests that the sodium loss from increased diuresis may 
help counteract some of the hypertension in diabetes (Maliha et al., 2014). However, diuresis can 
only account for blood pressure reduction in the short term. Rodent studies found that sodium 
levels in the distal convoluted tubule of the glomerulus normalize after 10-12 days of 
dapagliflozin administration (Thomson et al., 2012). Similar observations are seen in patients 
with T1D, in which hyperfiltration decreased allowing for increased diuresis, sodium excretion, 
and decreased short term blood pressure. (Cherney et al., 2014). 
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SGLT2 inhibition mediates blood pressure, part of which is due to increased sodium loss 
and decreased arterial stiffness with SGLT2 inhibition. As sodium levels decrease, plasma 
volume will decrease, and SBP should theoretically drop. In support, SGLT2 inhibition 
decreases risk of cardiovascular events and mortality (Birkeland et al., 2017). This is important 
because the presence and duration of diabetes leads to increased arterial stiffness and 
consequently elevated rates of cardiovascular, renal, retinal, and autonomic disease (Theilade et 
al., 2013).  
Risks of SGLT2 Inhibitors and Dapagliflozin 
Hypoglycemia 
Hypoglycemia is the condition of very low blood glucose concentrations. The risk for 
hypoglycemia is quite low when taking SGLT2 inhibitors. There is no increased risk of 
hypoglycemic episodes when dapagliflozin is used as a monotherapy; however, there is an 
increased hypoglycemic risk if dapagliflozin is taken in conjunction with sulfonylurea or insulin 
(exogenous) (Strojek et al., 2011; Vasilakou et al., 2013; Wilding et al., 2012). Insulin stimulates 
glucose uptake, while SGLT2 inhibitors increase glucosuria. These effects potentially compound 
one another leading to hypoglycemia (Wilding et al., 2012a). Therefore, decreased insulin 
dosage is required when supplemented with an SGLT2 inhibitor. 
Diabetic Ketoacidosis: 
Diabetic ketoacidosis (DKA) is an acute and serious complication of diabetes (Ogawa et 
al., 2016). Ketoacidosis is the result of hyperglycemia and high acidic concentrations of ketone 
bodies. While DKA often stems from hyperglycemia and insulin resistance, it can occur with 
moderate healthy increases in blood glucose concentrations (Ogawa et al., 2016). Numerous 
cases of DKA have been found in patients with either T1D or T2D when treated with an SGLT2 
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inhibitor (Hayami et al., 2015; Hine et al., 2015; Peters et al., 2015). SGLT2 inhibition instigates 
DKA through a cascade of events. By increasing glucosuria, blood glucose levels decrease. 
Lower blood glucose levels decrease insulin levels, which in turn increase lipolysis and free fatty 
acid (FFA) production. Increases in FFAs augment β-oxidation; thus, creating more ketone body 
production. Additionally, amplified glucagon levels and decreased insulin levels will reduce 
acetyl-CoA carboxylase activity, followed by an increase in carnitine palmitoyltransferase-1 
(CPT-1). Higher CPT-1 activity will instigate β-oxidation and ketone body production. Lastly, 
increased ketone body production will stimulate euglycemic DKA (Ogawa et al., 2016). 
Although DKA is a potential threat, there have been no reported cases of DKA in metabolically 
healthy individuals on SGLT2 inhibitors.  
The Effects of SGLT2 Inhibition on Energy and Appetite  
If the weight loss observed with SGLT2 inhibitors is less than hypothesized based on the 
glucosuria caloric loss, one would assume that SGLT2 inhibitors might increase hunger and 
appetite (Cefalu, 2014; Ferrannini et al., 2014; Zhang et al., 2014). It is likely that patients 
increase caloric intake rather than reduce energy expenditure when taking an SGLT2 inhibitor 
(Ferrannini et al., 2014). Evidence for increased caloric intake includes a shift in substrate 
oxidation from glucose to lipid but not accompanied by a change in energy expenditure when on 
SGLT2 inhibitors (Ferrannini et al., 2014).  
However, there are conflicting data on whether SGLT2 inhibitors instigate increased 
appetite and caloric consumption. Studies have failed to find an SGLT2 influence on energy 
intake (Bertran et al., 2018), yet have found an increase in sugar intake in patients with T2D 
(Horie et al., 2018). Regardless of caloric intake, numerous studies see increased desire for salty 
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and sweet foods (Bertran et al., 2018; Horie et al., 2018). This appetite change likely matches the 
natriuretic and glucuretic effects of the drug.  
 The conflicting results provide a potential direction for nutritional intervention when 
supplementing weight loss with dapagliflozin. By knowing the appetite and consumption for 
sweet sugary foods will increase, nutrition counselors can directly limit sugar consumption 
successfully achieving desired weight loss. Further research must investigate sugar restricted, 
dapagliflozin supplemented dietary counseling in both healthy and patients with T2D.  
Conclusion: 
 The use of SGLT2 inhibitors is associated with favorable modifications in body mass, 
beta-cell function, insulin sensitivity, and blood pressure. Dapagliflozin significantly influences 
weight loss in people with diabetes; however, the influence on metabolically healthy individuals 
is not heavily researched. If similar effects are seen in the metabolically healthy, SGLT2 
inhibition may provide supplemental benefits to life style changes in the prevention of metabolic 
disease. Hence the purpose of this study was to determine if SGLT2 inhibition will augment the 
effects of 12-weeks of dietary counseling for weight loss while simultaneously comparing 
modifications in glucose tolerance, blood pressure, appetite and satiety in overweight and obese 
adults with or without supplemented SGLT2 inhibition (dapagliflozin). We hypothesized that 
SGLT2 inhibition would potentiate the favorable influence of dietary counseling on body 






Over 415 million adults worldwide and 30.3 million people in the U.S.A. are currently 
diagnosed with T2D (Ogurtsova et al., ADA, 2017). Long term complications of T2D include 
retinopathy, neuropathy, and cardiomyopathy (Ahmad et al., 2016; Donahoe et al., 2007; Ritz & 
Orth, 1999; Roger et al., 2011; Singh et al., 2014). There is overwhelming evidence that physical 
inactivity and obesity are major determinants of developing T2D (King et al., 1990; Lindström et 
al., 2003; Manson et al., 1991). Therefore, lifestyle changes and/or pharmaceutical interventions 
aid in attenuating T2D symptom progression. Lifestyle regulates diabetes.  
One of the earlier pharmaceutical therapies and most commonly prescribed T2D drug is 
Metformin. If oral Metformin fails, insulin therapy is often supplemented as another 
pharmacological intervention for hyperglycemia (Inzucchi et al., 2014; Kilov et al., 2013). 
However, due to increasing insulin resistance, patients with T2D receiving insulin therapy often 
require increased dosage. Higher insulin doses potentially lead to negative side effects including 
weight gain, fluid retention, and hypoglycemic events (Rosenstock et al., 2012; Stenlöf et al., 
2013). Hence, there is a clear need for pharmacological therapy that will improve hyperglycemia 
yet prevent weight gain. In this regard, interest in a class of insulin independent drugs, sodium 
glucose cotransporter 2 (SGLT2) inhibitors, has flourished.  
Located in the proximal convoluted tubule of the kidney, SGLT2 regulates the 
reabsorption of glucose. A reduction in SGLT2 expression caused by either mutation or 
inhibition leads to glucosuria (DeFronzo et al., 2013; Kanai et al., 1994). By inhibiting SGLT2 
proteins and enhancing glucosuria, substantial calories (glucose) should be lost in urine. In 
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theory, this effect may simultaneously lead to cumulative loss of calories, which should result in 
weight loss and improve insulin sensitivity.  
Dapagliflozin is one of several SGLT2 inhibitors. Dapagliflozin induced glucosuria leads 
to a net caloric loss of up to 200-300 kcal/day (List et al., 2009). Administration of dapagliflozin 
over 24-102 weeks has been reported to decrease total body mass, fat mass, visceral adipose 
tissue, subcutaneous adipose tissue, waist circumference, and blood pressure, and improve 
glycemic control in patients with T2D (Bolinder et al., 2012; Wilding et al., 2012). Currently it is 
unclear whether these health benefits are due to SGLT2 inhibition or a secondary effect of 
weight loss.   
There are conflicting data on whether SGLT2 inhibitors increase appetite and caloric 
consumption. Some studies have failed to find an influence on energy intake (Bertran et al., 
2018), while others have found an increase in sugar intake in patients with T2D (Horie et al., 
2018). Likely matching the natriuretic and glucuretic effects of the drug, numerous studies report 
an increased desire for salty and sweet foods (Bertran et al., 2018; Horie et al., 2018).   
Several studies have investigated dapagliflozin in healthy diabetes-free individuals: 
pharmacokinetic characteristics (Komoroski et al., 2009; Yang et al., 2013), influence on 
appetite (Bertran et al., 2018), and exercise training (Newman et al., 2018). However, no study 
has specifically tested the influence of SGLT2 inhibition on weight loss in healthy individuals. 
Hence the purpose of this study is to determine if SGLT2 inhibition will augment the effects of 
12-weeks of dietary counseling for weight loss while simultaneously comparing modifications in 
glucose tolerance, blood pressure, appetite and satiety in overweight and obese adults with or 
without supplemented SGLT2 inhibition (dapagliflozin). We hypothesized that SGLT2 inhibition 
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would potentiate the favorable influence of dietary counseling on body composition and 








A double-blind, repeated measures parallel design was employed incorporated with 
stratified random assignment. All procedures were approved by the Institutional Review Board at 
Colorado State University, Fort Collins in agreement with the principles originating from the 
Declaration of Helsinki.  
Participants 
Overweight and obese sedentary but otherwise healthy men and women volunteered and 
participated. Inclusion criteria included: provision of informed consent, aged between 18-65 
years, body mass index (BMI) within the range of 27.5-45 kg/m2, no significant exercise training 
(maximum of 3 physical activity sessions/week of less than or equal to 30 minutes per session 
over the previous year), negative pregnancy test for women of childbearing potential, no known 
metabolic diseases, and willingness to modestly reduce daily caloric intake for twelve weeks. 
Exclusion criteria were evidence of any significant disease that may interfere with study 
objectives, use herbal preparations or prescription drugs other than birth control, and/or 
medications to treat depression, current enrollment in another clinical study, habitual or recent 
use of tobacco in the last two years, history of hypersensitivity reaction to Dapagliflozin, severe 
renal impairment, pregnant, abnormal liver function, bilirubin > 2.0 mg/dL (34.2 umol/L), 
Hepatitis B or C antibodies or antigens, history of bladder cancer, recent cardiovascular events, 




Following screening and prior to and after a 12-weeks of dietary counseling for weight 
loss supplemented with daily ingestion of either placebo or SGLT2 inhibitor (Dapagliflozin), 
participants were assessed for body mass and composition, resting metabolic rate, insulin 
sensitivity (oral glucose tolerance test), and hunger and appetite. 
Table 1: Outline of Study Visits 
Weeks -2 to 0 Weeks 1-12 Week 13 
Screening, 






















DEXA: Dual Energy X-ray Absorptiometry 
OGTT: Oral Glucose Tolerance Test 
RMR: Resting Metabolic Rate 
Screening 
Screening included: review of medical history, graded exercise stress test (rest to 
volitional fatigue) with 12-lead electrocardiogram, blood pressure assessment, blood sample 
(liver enzymes, fasting glucose concentrations, and hepatitis C). Peak oxygen consumption 
(VO2peak) was measured during constant ramp protocol graded exercise stress test on stationary 
cycle ergometer (Dynafit Velotron; Racermate Inc., Seattle, USA) (Richards et al., 2010). With 
the goal of a 8-12 minute test, the specific ramp protocol was chosen at the researchers’ initial 
impression of the participants’ fitness. Wattage increases were between 15-30 Watts/min.  Every 
two minutes heart rate, blood pressure, rating of perceived exertion (RPE) (Borg, 1982) were 
measured. The test was terminated at volitional fatigue or once pedal cadence fell below 40 
revolutions/min. Expired gases and ventilation were measured continuously with a metabolic cart 
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(Parvo Medics, Sandy, Utah, USA). The highest four consecutive 15-s average VO2 values were 
used to calculate VO2peak. 
Body Composition 
Body composition was assessed using dual energy x-ray absorptiometry (DEXA: Hologic 
Discovery W, QDR Series, Bedford, MA, USA) (Scalzo et al., 2014). Body mass was assessed 
using a physician’s digital scale. Waist circumference was measured midway between the lower 
border of the costal margin and the uppermost border of the iliac crest. Hip circumference was 
measured around widest portion of hips and gluteus maximus. Both waist and hip circumference 
was measured three times each and then averaged.  
Resting Metabolic Rate & Oral Glucose Tolerance Test 
Following a 12-hour fast and 24-hour abstention from exercise and caffeine, participants 
reported to the laboratory for assessment of resting metabolic rate (RMR) and completion of an 
oral glucose tolerance test (OGTT). On arrival, body mass was measured using a physician’s 
digital scale. Participants were then placed in a dimly lit room and expired air was collected and 
used to calculate RMR and respiratory exchange ratio (RER) (Mass Spectrometry: MA Tech 
Services, INC. Saint Louis, Missouri, USA)) over a period of forty-five minutes (only the last 30 
minutes of collection was used for RMR/RER calculations). Blood pressure was measured three 
times during the forty-five-minute period (once every 15 minutes) with accuracy of ± 3 mmHg 
(HEM-7113: Omron Healthcare Asia). RMR was calculated using the Weir Equation (RMR = 
((3.9 x VO2) + (1.1 x VCO2)) x 1.44). Where VO2 is the rate of oxygen consumption (ml/min) 
and VCO2 is the rate of carbon dioxide production (ml/min). 
After completion of the RMR, a venous catheter was placed in an antecubital or hand 
vein. Following baseline blood sampling (20 mL), participants ingested 75 grams of glucose 
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diluted in 300 mL water. Venous blood was sampled over the next two hours (20 mL at minutes 
15, 30, 60, 75, 90, 120 & 1 mL at minutes 0, 5, 10, 20, 45, 105) for determination of circulating 
concentrations of glucose (2900 STAT Plus Glucose Lactate Analyzer, YSI Inc., Yellow 
Springs, Ohio, USA) and insulin (enzyme-linked immunosorbent assay; Crystal Chem, Inc., Elk 
Grove, Village, Illinois, USA) (Beals et al., 2017; Newman et al., 2018). Insulin sensitivity was 
estimated by Matsuda Index (10,000/square root of ((fasting glucose x fasting insulin) x ( mean 
glucose x mean insulin during OGTT))) (Matsuda et al., 1999). 500 ul of serum and plasma were 
isolated and transferred into six phials each. Two phials containing plasma were cocktailed with 
protease inhibitor (10 ul DPP and 10 ul Sigma Pi) and 500 ul serum were immediately placed in 
a -80 C freezer. 
Hunger and Appetite Assessment  
Following a 12-hour fast and 24-hour abstention from exercise and caffeine, participants 
reported to the clinical laboratory and upon arrival, a venous catheter was placed in an 
antecubital or hand vein and 20 mL of blood was drawn for baseline measurements. Participants 
then ingested 1 kilocalorie/kg body mass of a small mixed macronutrient liquid meal, consisting 
of Ensure (24% fat, 60% carbohydrate, 16% protein). Sixty minutes after the liquid preload, 
participants selected food from an all-you-can-eat breakfast buffet. Participants were allowed 20 
minutes to eat. The selected food choices (packaging included) were recorded and weighed 
before and after participant consumption. Remaining uneaten food was reweighed and 
participants’ energy and macronutrient intakes were determined using the Food Intake Analysis 
System software (U Texas Health Sciences Center, Houston). Participants remained at the 
facility for the next three hours for follow up blood and satiety measurements. 20 ml of blood 
was draw 60 minutes prior to the priming meal and buffet, and then every 60 minutes for 3 
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hours. Blood was immediately assayed for concentrations of glucose (2900 STAT Plus Glucose 
Lactate Analyzer, YSI Inc., Yellow Springs, Ohio, USA). 500 ul of plasma cocktailed with 
protease inhibitor (10 ul DPP and 10 ul Sigma Pi) and 500 ul serum were immediately placed in 
a -80 C freezer.  
At baseline, 0 and 60 minutes after liquid meal consumption, and 0, 60, 120, and 180 
minutes after breakfast, participants completed a hunger and satiety survey. Surveys consisted of 
five questions: (1) How strong is your desire to eat right now? (2) How hungry do you feel right 
now? (3) How full do you feel right now? (4) How much do you think you could eat right now? 
(5) How thirsty do you feel right now?  Subjects answered these questions by marking a vertical 
line on a 100 mm visual analog scale  (Paris et al., 2016). 
Treatment 
Research participants were assigned, in a double-blind fashion, via stratified random 
sampling into one of two treatment groups: placebo or the SGLT2 inhibitor, Dapagliflozin, via 
coin flip until one treatment group had 25 participants, after which all remaining participants 
were assigned the other treatment. A stratified random assignment was used to balance sex 
distribution between groups. Oral ingestion of treatment or placebo coincided with the first day 
of counseling and ended on the last day of counseling. The dose of Dapagliflozin began at 5 
mg/day for the first two weeks. The dose was increased to 10 mg/day in the absence of adverse 
events for the remainder of the study. An identical dosing procedure was used previously 
(Newman et al., 2018). 
Dietary Counseling 
Participants completed a three-day diet log before initiation of counseling. Diet logs and 
recalls included all food and drink consumed (ingredients and amounts), location of meal, time 
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of day, and hunger level before meal. Commercially available software (NutritionistPro, Axxya 
Systems, Redmond, WA) was used to determine the caloric and micro- and macro-nutrient make 
up of each item consumed. Dietary counseling consisted of weekly, one-on-one, 30-minute 
meetings targeting calorie restriction. Counseling focused on modest caloric restriction initially 
equal to resting metabolic rate multiplied by an activity factor of 1.2 and then lowered over to 
time to a kilocalorie target equal to the measured baseline resting metabolic rate. This dietary 
reduction was designed to reduce each participant’s weight by approximately 0.5kg per week 
(Paris et al., 2016). Prescribed macronutrient intake comprised of approximately 50% 
carbohydrates, 30% fat, and 20% protein, while maintaining adequate micronutrient intakes (90-
100% of recommended dietary allowance). Dietary counseling focused on methods of mindful 
eating while also teaching techniques to decrease energy density and intake of convenience 
commercially-prepared foods high in added sugar and fat, and to increase fiber intake and water 
consumption. Additionally, participants were instructed to maintain current activity levels and 
discouraged from beginning a program of exercise.  During weeks 5 and 10, participants 
completed a 24-h diet recall under the supervision of counselor for the purpose of identifying 
strategies to enhance dietary objectives, 
Blinding Procedures: 
Pill bottles containing Dapagliflozin were labeled as “A” or “B”. The clinical trials 
administrator was responsible for ensuring blinding of both participants and researchers. Neither 





Baseline (pre-counseling) differences between placebo and SGLT2 inhibition groups 
were determined via one-way Analysis of Variance (ANOVA). The influence of Dapagliflozin 
on physiological responses to dietary counseling was examined via two-way repeated measures 
ANOVA (placebo vs. Dapagliflozin x before vs. after dietary counseling). The influence of 
Dapagliflozin and counseling on dynamic changes to hunger, appetite, and oral glucose ingestion 
was examined using three-way ANOVA (placebo vs. Dapagliflozin x before vs. after dietary 
counseling x time). Pairwise comparisons were performed via the Tukey Method. Outliers were 
determined using Median Absolute Deviation (MAD) (Leys et al. 2013). Relationships of 
interest were calculated using a Pearson Correlation. The level of statistical significance was set 
a P < 0.05. Data were reported as mean and standard deviation, unless indicated differently. 
Calculations were performed using SigmaStat 3.0 (Systat Software Inc., San Jose, California, 







50 participants completed the study; baseline physiological characteristics are presented 
in Table 2. Consistent with exclusion and inclusion criteria, participants portrayed characteristics 
of sedentary overweight/obese, but otherwise healthy adults. There were no baseline differences 
in any primary variables between placebo and SGLT2 Inhibitor groups. 
Body Composition 
 Body mass and composition are presented in Figure 2 and Table 3. Twelve weeks 
of dietary counseling decreased body mass, BMI, and fat mass (P < 0.001); neither variable was 
influenced by pill assignment (interaction: P > 0.385) (Figure 2A, B, C). Dietary counseling also 
decreased lean mass (treatment main effect: P < 0.001), however the decrease in lean mass was 
greater in Pill B than in Pill A (interaction: P = 0.037) (Figure 2D). Counseling increased bone 
mineral content (P=0.027); SGLT2 inhibition did not influenced this interaction (P=0.807) 
(Figure 2E). 
Resting Metabolic Rate  
RMR and RER data are presented in Figure 3 and Table 4. RMR and RER both 
decreased in response to dietary counseling (P<0.049); SGLT2 inhibition did not influence either 
outcome (P>0.397) (Figure 3A & 3B). ANCOVA results demonstrated the change in lean mass 
does not explain the change in RMR (P=0.8423). The changes in RMR and lean mass are not 
correlated (P=0.881 and r=0.022). 
Glucose and Insulin 
Glucose and Insulin data are presented in Figure 4 and Tables 1 and 4. Based on the 
Median Absolute Deviation (MAD) method (Leys et al. 2013) for determining outliers, baseline 
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insulin data were considered an outlier if greater than 17.21 mU/L. Four baseline insulin  values 
(17.77, 19.64, 38.29, and 86.05 mU/L) were considered outliers and removed from all further 
insulin analysis. Any magnitude changes in baseline insulin from Week 0 to Week 12 over 5.82 
mU/L for Pill A and 6.35 mU/L for Pill B were considered outliers. One delta value (7.40 mU/L) 
was removed from Pill A. A Matsuda Index value greater than 18.35 and a change in Matsuda 
Index greater than 9.64 for Pill A and 8.77 for Pill B constituted an outlier. Four Week 0 
Matsuda scores were removed from analysis: two from Pill A (29.19 and 33.76) and two from 
Pill B (29.89 and 55.47). Five additional Matsuda scores were considered outliers because the 
magnitude of change exceeded the threshold criteria for being an outlier (Pill A: 24.02 and 13.15, 
Pill B: 10.04, 17.29, and 18.98). 
Baseline fasting glucose and insulin were similar between placebo and SGLT2 inhibition 
groups (P>0.143) (Figure 4A & 4B). While there was no main effect of drug interaction on the 
circulating glucose response to glucose ingestion (P > 0.93), one-hour area under the curve 
(AUC) of circulating glucose concentrations decreased with dietary counseling (P = 0.036) 
(Figure 4C). There was no difference in glucose 2nd hour AUC (P = 0.14). Dietary counseling 
decreased circulating insulin concentrations and insulin AUC (P<0.009); SGLT2 inhibition had 
no influence on this outcome (P>0.089) (Figure 4B, 4D, & 4F). Neither dietary counseling nor 
SGLT2 inhibition influenced Matsuda Index (P > 0.055). Additionally, the amount of weight lost 
and magnitude of change in insulin sensitivity were not correlated (P=0.775 and r=0.048). 
Hunger and Appetite 
 Circulating glucose concentrations, total caloric intake and the macronutrient distribution 
of food consumed over 20 minutes during the all-you-can-eat buffet, heart rate, and blood 
pressure responses during hunger and appetite assessment are all presented in Figure 5A, 5B, and 
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Table 5. Dietary counseling favorably modified glucose AUC (P=0.022) and heart rate at all time 
points (P<0.037), but no effect on SBP or DBP (P>0.056); SGLT2 inhibition did not influence 
these outcomes (P>0.233). However, SGLT2 inhibition did influence heart rate sixty minutes 
post buffet (P=0.036). At baseline, those taking Pill A consumed more total calories for fat, 
carbohydrate, and protein. (P<0.028). Dietary counseling decreased total calories consumed from 
fat (P=0.011); SGLT2 inhibition did not influence this outcome (Figure 5 & Table 5).  
Participant satiety responses are present in Table 6 and Figure 6. Dietary counseling 
decreased perceived hunger and increased satiety 60 minutes post “Primer” meal (P<0.044); 
SGLT2 inhibition did not influence this outcome (P>0.526).  
Diet Logs 
Participant diet log and diet recall data are found in Table 7 and Figure 7. Dietary 
counseling decreased self-reported total caloric intake and carbohydrate and fat consumption 
(P<0.005); SGLT2 inhibition influenced total caloric intake and carbohydrate consumption 
(P<0.041). Post hoc Tukey analysis indicates SGLT2 inhibition influenced differences at Week 0 
(P=0.013). Percentage of calories consumed by protein increased post counseling (P=0.017); 
SGLT2 inhibition did not influence this interaction (P=0.201). Percentage of calories from fat 





Table 2: Selected Baseline Physiological Characteristics  
 Pill A (Mean ±SD) Pill B (Mean ± SD) P-Value 
Male/Female 7/18 5/20 - 
Age (years) 35 ± 11 38 ± 11 0.362 
Height (cm) 167 ± 9 169 ± 8 0.399 
Body Mass (kg) 93.75 ± 20.43 96.47 ± 15.60 0.388 
BMI (kg/m2) 33.24 ± 5.61 33.50 ± 3.85 0.858 
Body Fat (%) 39.80 ± 5.99 41.76 ± 5.16 0.222 
Blood Pressure (mmHg) 112/69 ± 8/5 116/69 ± 10/8 0.066/0.819 
VO2peak (ml/kg/min) 24.75 ± 5.60 22.24 ± 4.97 0.100 
Fasting Glucose (mg/dL 74.70 ± 6.93 76.08 ± 7.67 0.508 
Fasting Insulin (mU/L) 5.12 ± 2.47 6.98 ± 3.90 0.120 
Data: Mean ± SD 
BMI: Body Mass Index 
VO2peak: Peak Oxygen Uptake 
 
 
Table 3: Body Composition Derived Data Before and After 12-Weeks of Dietary 
Counseling Supplemented With or Without Sodium Glucose Co-Transport 2 Inhibition 









Group Counseling Interaction 
Body Mass (kg) 93.75 ± 20.43 90.31 ± 19.72 96.47 ± 15.60 92.14 ± 16.73 0.660 <0.001 0.394 
BMI (kg/m2) 33.24 ± 5.61 32.00 ± 5.43 33.50 ± 3.85 31.97 ± 4.27 0.936 <0.001 0.446 
WC (cm) 92.3 ± 10.2 90.7 ± 8.2 95.6 ± 9.0 94.2 ± 10.8 0.239 0.052 0.902 
HC (cm) 115.8 ± 12.6 111.6 ± 9.4 119.9 ± 10.0 116.3 ± 10.3 0.066 <0.001 0.173 
WHR 0.83 ± 0.93 0.81 ± 0.06 0.80 ± 0.73 0.81 ± 0.07 0.634 0.194 0.242 
BMC (kg) 2.43 ± 0.37 2.46 ± 0.39 2.57 ± 0.32 2.59 ± 0.33 0.181 0.027 0.807 
Fat Mass (kg) 36.95 ± 11.38 34.97 ± 11.23 40.13 ± 8.96 37.91 ± 10.26 0.306 <0.001 0.77 
Lean Mass (kg) 52.83 ± 10.85 52.19 ± 11.10 52.97 ± 8.90 50.97 ± 9.04 0.848 <0.001 0.037 
FFM (kg) 55.26 ± 11.17 54.59 ± 11.44 55.54 ± 9.16 53.56 ± 9.30 0.897 <0.001 0.047 
Body Fat (%) 39.80 ± 5.99 38.73 ± 6.84 41.76 ± 5.16 41.13 ± 6.00 0.202 0.001 0.385 
Data: Mean ± SD 
WC: Waist Circumference 
HC: Hip Circumference 
WHR: Waist Hip Ratio 
FFM: Fat Free Mass  
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Table 4: RMR and OGTT Derived Data Before and After 12-Weeks of Dietary Counseling 
Supplemented With or Without Sodium Glucose Co-Transport 2 Inhibition 





Post-Counseling Group Counseling Interaction 
RMR 1636 ± 282 1543 ± 262 1610 ± 235 1572 ± 310 0.982 0.049 0.397 
RER 0.90 ± 0.05 0.86 ± 0.07 0.88 ± 0.05 0.84 ± 0.06 0.228 0.002 0.898 
GLUCOSE        
  Fasting Glucose 74.70 ± 6.93 75.00 ± 7.84 76.08 ± 7.67 72.59 ± 5.54 0.857 0.512 0.261 
  AUC 12966 ± 2703 12419 ± 2431 12711 ± 1968 12111 ± 1974 0.625 0.062 0.93 
  AUC 0-1 Hr. 6295 ± 955 5966 ± 854  6216 ± 731 5977 ± 885 0.871 0.036 0.735 
  AUC 1-2 Hr. 6672 ± 1853 6453 ± 1737 6494 ± 1401 6133 ± 1322 0.545 0.14 0.713 
INSULIN        
  Fasting Insulin 5.12 ± 2.47 4.76 ± 2.43 6.98 ± 3.90 5.62 ± 3.33 0.134 0.009 0.125 
  AUC 6331 ± 4724 5510 ± 3232 8292 ± 5062 5694 ± 3375 0.356 0.002 0.089 
  AUC 0-1 Hr. 2960 ± 2539 2390 ± 1500 3729 ± 2280  2666 ± 1822 0.376 <0.001 0.254 
  AUC 1-2 Hr. 3371 ± 2328 3121 ± 1909 4564 ± 3157 3028 ± 1744 0.390 0.009 0.056 
MATSUDA 
INDEX 
8.94 ± 4.27 8.61 ± 3.48 6.27 ± 3.66 7.84 ± 3.16 0.135 0.209 0.055 
Data: Mean ± SD 
RMR: Resting Metabolic Rate 
RER: Respiratory Exchange Ratio 
Units for RMR: kcal/day 
Units for glucose: mg/dL 
Units for Insulin: mU/L 
Glucose area under the curve units: mg/dL/min 




Table 5A: Hunger and Appetite Test Glucose and Energy Intake Derived Data Before and 
After 12-Weeks of Dietary Counseling Supplemented With or Without Sodium Glucose 
Co-Transport 2 Inhibition 









Group Counseling Interaction 
Glucose (mg/dL)        
Baseline 77.68 ± 7.68 76.24 ± 8.96 77.29 ± 7.32 74.24 ± 6.18 0.513 0.058 0.49 
Pre-Buffet 79.85 ± 13.80 78.39 ± 16.79 79.43 ± 14.05 77.63 ± 
11.58 
0.867 0.402 0.928 
Post-Buffet (0) 87.93 ± 14.45 84.73 ± 13.98 89.52 ± 14.60 80.55 ± 
10.18 
0.688 0.005 0.165 
Post Buffet (60) 83.82 ± 20.31 88.58 ± 20.07 87.26 ± 19.18 80.04 ± 
14.79 
0.495 0.816 0.051 
Post-Buffet (120) 85.17 ± 17.38 78.97 ± 15.19 80.52 ± 11.86 75.75 ± 7.82 0.241 0.006 0.714 
Post-Buffet (180) 81.98 ± 12.32 78.65 ± 13.42 79.11 ± 8.22 73.88 ± 6.49 0.145 0.006 0.524 
AUC Post Buffet 15236 ± 2611 14954 ± 2424 15127 ± 2252 13980 ± 
1474 
0.333 0.022 0.16 
Energy Intake        
Fat 163 ± 70 132 ± 64 122 ± 99 92 ± 64 0.028 0.011 0.977 
CHO 426 ± 187 431 ± 235 345 ± 130 297 ± 141 0.018 0.389 0.29 
Protein 119 ± 38 114 ± 62 96 ± 51 82 ± 33 0.022 0.169 0.512 
Total 693 ± 208 660 ± 313 549 ± 209 458 ± 184 0.004 0.059 0.381 
Data: Mean ± SD 
Units for glucose: mg/dL 
Units for energy intake: kcal  
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Table 5B: Hunger and Appetite Test Cardiovascular Derived Data Before and After 12-
Weeks of Dietary Counseling Supplemented With or Without Sodium Glucose Co-
Transport 2 Inhibition 









Group Counseling Interaction 
Heart Rate        
Pre-Buffet 69 ± 8 64 ± 10 67 ± 7 63 ± 7 0.446 0.002 0.802 
Post-Buffet (0) 70 ± 10 66 ± 10 71 ± 8 66 ± 7 0.89 <0.001 0.551 
Post Buffet (60) 78 ± 10 72 ± 16 73 ± 7 70 ± 7 0.14 <0.001 0.036 
Post-Buffet (120) 73 ± 10 72 ± 11 70 ± 6 67 ± 7 0.047 0.037 0.477 
Post-Buffet (180) 71 ± 9 68 ± 10 69 ± 9 65 ± 5 0.271 0.007 0.716 
SBP        
Baseline 117 ± 9 119 ± 8 122 ± 11 122 ± 10 0.086 0.376 0.821 
Pre-Buffet 117 ± 7 120 ± 9 121 ± 12 119 ± 11 0.509 0.768 0.262 
Post-Buffet (0) 121 ± 9 123 ± 7 125 ± 11 124 ± 11 0.195 0.686 0.449 
Post Buffet (60) 119 ± 9 115 ± 10 122 ± 10 119 ± 9 0.099 0.061 0.494 
Post-Buffet (120) 118 ± 8 117 ± 9 121 ± 10 119 ± 14 0.242 0.560 0.983 
Post-Buffet (180) 118 ± 8 117 ± 10 123 ± 13 122 ± 12 0.057 0.568 0.815 
DBP        
Baseline 74 ± 6 75 ± 7 76 ± 12 74 ± 11 0.705  0.819 0.377 
Pre-Buffet 74 ± 6 74 ± 7 75 ± 9 72 ± 9 0.935 0.393 0.286 
Post-Buffet (0) 73 ± 6 76 ± 5 74 ± 9 74 ± 9 0.774 0.260 0.233 
Post Buffet (60) 72 ± 7 69 ± 8 73 ± 9 72 ± 9 0.318 0.086 0.373 
Post-Buffet (120) 71 ± 8 72 ± 7 70 ± 8 73 ± 8 0.948 0.079 0.299 
Post-Buffet (180) 73 ± 6 73 ± 6 73 ± 11 75 ± 9 0.654 0.276 0.621 
Data: Mean ± SD 
Units for Heart Rate: Beats/Min 
SBP/DBP: Systolic Blood Pressure/Diastolic Blood Pressure 





Table 6: Satiety Questionnaire Derived Data Before and After 12-Weeks of Dietary 
Counseling Supplemented With or Without Sodium Glucose Co-Transport 2 Inhibition 









Group Counseling Interaction 
Baseline        
Q1 49 ± 26 52 ± 29 37 ± 30 37 ± 30 0.069 0.735 0.646 
Q2 49 ± 25 50 ± 29 35 ± 29 35 ± 28 0.041 0.892 0.892 
Q3 20 ± 14 23 ± 17 26 ± 23 22.16 ± 18 0.583 0.994 0.215 
Q4 50 ± 14 53 ± 23 49 ± 25  42 ± 22 0.247 0.571 0.098 
Q5 51 ± 19 57 ± 22 56 ± 24 60 ± 22 0.414 0.213 0.658 
Post-Meal 
Primer (0) 
       
Q1 47 ± 24 46 ± 26 34 ± 24 32 ± 26 0.023 0.816 0.789 
Q2 47 ± 24 48 ± 25 35 ± 26 29 ± 24 0.010 0.678 0.24 
Q3 25 ± 14 30 ± 15 30 ± 21 35 ± 21  0.216 0.089 0.951 
Q4 49 ± 18 51 ± 22 47 ± 22 39 ± 25 0.160 0.57 0.054 
Q5 45 ± 17 52 ± 22 48 ± 24 54 ± 23 0.687 0.082 0.884 
Post-Meal 
Primer (60) 
       
Q1 54 ± 19 48 ± 24 44 ± 24 38 ± 21 0.077 0.075 0.9 
Q2 53 ± 18 53 ± 21 42 ± 25 39 ± 20 0.016 0.565 0.663 
Q3 21 ± 12 28 ± 16 27 ± 16 31 ± 18 0.237 0.044 0.526 
Q4 57 ± 13 51 ± 20 52 ± 17 44 ± 19 0.152 0.015 0.582 
Q5 48 ± 18 53 ± 21 59 ± 20 58 ± 19 0.103 0.446 0.276 
Post-Buffet 
(0) 
       
Q1 14 ± 14 11 ± 10 8 ± 9 12 ± 8 0.388 0.768 0.193 
Q2 12 ± 12 11 ± 11 6 ± 6 8 ± 7 0.033 0.87 0.468 
Q3 68 ± 15 67 ± 20 72 ± 14 72 ± 18 0.271 0.871 0.782 
Q4 17 ± 14 13 ± 10  14 ± 15 14 ± 14 0.762 0.333 0.551 
Q5 34 ± 21 37 ± 23  41 ± 24 42 ± 22 0.271 0.561 0.831 
Post-Buffet 
(60) 
       
Q1 15 ± 15 15 ± 14 11 ± 8 11 ± 9 0.158 0.795 0.952 
Q2 12 ± 9 14 ± 15 10 ± 9 10 ± 9 0.29 0.563 0.689 
Q3 62 ± 19 63 ± 19 57 ± 22 56 ± 21 0.218 0.929 0.78 
Q4 20 ± 14 19 ± 17 21 ± 17 19 ± 16 0.854 0.373 0.845 
Q5 38 ± 19 43 ± 22 40 ± 18 48 ± 17 0.409 0.03 0.585 
Post-Buffet 
(120) 
       
Q1 22 ± 16 24 ± 14 22 ± 18 15 ± 13 0.265 0.345 0.044 
Q2 20 ± 15 20 ± 14 21 ± 14 15 ± 10 0.425 0.222 0.235 
Q3 54 ± 20 56 ± 17 52 ± 22 49 ± 20 0.336 0.938 0.429 
Q4 20 ± 19 24 ± 14 30 ± 18 28 ± 18 0.624 0.211 0.603 
Q5 43 ± 21 44 ± 20 46 ± 18  50 ± 18 0.528 0.372 0.74 
Post-Buffet 
(180) 
       
Q1 35 ± 20 36 ± 19 33 ± 24 25 ± 20 0.2 0.249 0.116 
Q2 35 ± 20 36 ± 20 34 ± 25 25 ± 21 0.254 0.12 0.105 
Q3 43 ± 15 48 ± 18 41 ± 20 40 ± 20 0.205 0.499 0.324 
Q4 40 ± 13 36 ± 18 40 ± 19 33 ± 21 0.645 0.053 0.693 
Q5 47 ± 21 47 ± 23 52 ± 17 56 ± 18 0.149 0.511 0.561 
Data: Mean ± SD 
Units for all scores: mm 
Q1: How strong is your desire to eat right now? 
Q2: How hungry do you feel right now? 
Q3: How full do you feel right now? 
Q4: How much do you think you could eat right now? 
Q5: How thirsty do you feel right now?  
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Table 7: Dietary Logs and Recall Data Derived in Week 0, Week 5, and Week 10 of Dietary 
Counseling 
 Pill A Pill B ANOVA P-Values 
 Week 0 Week 5 Week 10 Week 0 Week 5 Week 10 Group Counseling Interaction 












0.236 <0.001 0.041 
Protein (g) 85 ± 24  74 ± 29  82 ± 40  80 ± 25  74 ± 31 78 ± 36  0.656 0.299 0.886 
CHO (g) 246 ± 73 167 ± 61 173 ± 78 197 ± 59  186 ± 79 160 ± 62 0.316 <0.001 0.019 
Fat (g) 91 ± 28 68 ± 23 70 ± 24 77 ± 26  72 ± 39  65 ± 31  0.425 0.005 0.251 
Protein (%) 16 ± 3 19 ± 8 20 ± 8 18 ± 5 18 ± 6 20 ± 7 0.73 0.017 0.201 
CHO (%) 45 ± 9 42 ± 10 42 ± 13 43 ± 7 44 ± 9 41 ± 11 0.999 0.244 0.423 
Fat (%) 37 ± 7 38 ± 10 39 ± 11 38 ± 7 37 ± 9  38 ± 11 0.805 0.817 0.705 








Figure 2: Dietary counseling favorably modifies body mass and composition; SGLT2 
inhibition does not influence any of these adaptations except for lean mass. A. Body mass. B. 
Body mass index. C. Fat mass. D.% Body Fat. E. Lean Body Mass. F. Bone Mineral Content. 
G. Total Fat Free Mass. In all graphs Pre and Post refer to data collected before and after 12-
weeks of dietary counseling. Large dark filled circles and large open white circles represent 
mean responses for placebo and SGLT2 inhibition, respectively. Circles connected via dotted 
lines represent individual participants pre and post intervention. See Table 3 for results of 




Figure 3: Dietary counseling decreases RMR and RER; SGLT2 inhibition does not influence 
any of these adaptations except for lean mass. A. RMR. B. RER. In all graphs Pre and Post 
refer to data collected before and after 12-weeks of dietary counseling. Large dark filled 
circles and large open white circles represent mean responses for placebo and SGLT2 
inhibition, respectively. Circles connected via dotted lines represent individual participants 




Figure 4: Dietary counseling favorably modifies baseline circulating insulin and insulin AUC; 
SGLT2 inhibition does not influence these adaptations. A. Baseline blood glucose 
concentration. B. Baseline blood insulin concentration. C. Circulating glucose concentrations 
during OGTT (post 75 g of glucose ingestion). D. Circulating insulin concentrations during 
OGTT (post 75 g of glucose ingestion). E. OGTT Glucose AUC. F. OGTT Insulin AUC. G. 




Figure 5: Dietary counseling favorably modifies glucose regulation and heart rate and 
decreases fat intake; SGLT2 inhibition does not influence these adaptions or outcomes. A. 
Circulating glucose concentration during hunger and appetite assessment. B. Food 
consumption in kcal for 20 minutes all-you-can-eat breakfast buffet. C. Systolic blood 
pressure D. Diastolic blood pressure. E. Heart rate responses See Table 5 for data and 




Figure 6: Dietary counseling has no effect on appetite or satiation; SGLT2 has no influence 
on these outcomes. A. Question 1. B. Question 2. C. Question 3. D. Question 4. E. Question 
5. All panels are time course during hunger and appetite assessment. Specific content of each 





Figure 7: Dietary counseling decreases total caloric consumption, specifically by decreasing 
carbohydrate and fat intake; SGLT2 inhibition does not influence these outcomes. See Table 






 The purpose of the current study was to determine if SGLT2 inhibition would augment 
the effects of 12-weeks of dietary counseling. Twelve weeks of dietary counseling favorably 
modified body mass, fat mass, and heart rate; SGLT2 inhibition did not influence any of these 
outcomes. The novel observation of the current study is SGLT2 inhibition neither augmented nor 
attenuated the beneficial physiological outcomes; however, Pill A attenuated the loss of lean 
mass or Pill B exacerbated the loss of lean mass. 
Body Composition 
 There is overwhelming evidence that obesity is a major determinant in the development 
of Type 2 Diabetes (King et al., 1990; Lindström et al., 2003; Manson et al., 1991). Excess 
adipose tissue is associated with ectopic lipid accumulation resulting in lipotoxicity, the 
damaging effects of excess fat accumulation on glucose metabolism (DeFronzo, 2010; Unger, 
2003). Therefore, by promoting glucosuria and weight loss, SGLT2 inhibition can theoretically 
reverse the lipotoxic effects on insulin sensitivity. In the current study, SGLT2 inhibition did not 
influence the favorable modification of body composition with dietary counseling. However, Pill 
B exacerbated the loss of lean mass.  
Patients with T2D have elevated renal glucose reabsorption compared to their healthy 
counterparts (Gerich, 2010; Liang et al., 2012; Meyer et al., 1998; Meyer et al., 2004; Mogensen, 
1971; Rave et al., 2006; Ruhnau et al., 1997; Tabatabai et al., 2009; Wilding et al., 2014). Thus, 
SGLT2 inhibition may have a greater magnitude of change on patients with T2D than in healthy 
adults. A person without T2D already has normal glucose excretion. Therefore, glucosuria will 
theoretically enhance weight loss by increasing urinary excretion of calories as glucose. 
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Unfortunately, this investigation did not measure the amount of glucose excreted with and 
without SGLT2 inhibition. Future research needs to quantitatively compare the magnitude of 
influence on renal glucose excretion between patients with T2D and healthy adults.  
 Dietary-induced weight loss is typically accompanied by a decline in skeletal muscle 
mass (Bopp et al., 2008; Cava et al., 2017). The current investigation found that Pill B 
exacerbated the loss of lean mass during dietary counseling for weight loss. It is expected that 
SGLT2 inhibition may enhance loss of lean mass through urinary glucose excretion. When 
glucose is excreted, the energy demanding tissues turn to fat and protein as alternate sources of 
fuel; hence increasing protein degradation (Cava et al., 2017). Additionally, with less circulating 
glucose and in caloric deficit, the rate of glycogenolysis increases causing a decrease in muscle 
glucose storage (Berg et al, 2002). Although the muscle glycogen stores only make up about 1-
2% of muscle mass, a 70kg person can store roughly 400 grams of glycogen (Wasserman, 2009). 
In fact, the average lean body mass in the current study was 52.83 kg. If glycogen accounts for 1-
2% of lean mass, participants potentially lost between 0.5-1 kg of lean mass due to glycogen 
depletion. If SGLT2 inhibition increases lean mass loss, it may be important for those taking 
SGLT2 inhibitors to increse protein consumption. Protein consumption is known to attenuate 
lean mass loss during caloric restriction (Cava et al., 2017; Pasiakos et al., 2013; Phillips et al., 
2012; Verreijen et al., 2015). In order to remedy the observed loss of lean mass, future studies 
should investigate high protein dietary weight loss supplemented with SGLT2 inhibitors. Until 
further investigation, baseline lean mass health status and final goals for weight loss with SGLT2 
inhibition require consideration prior to initiation.   
A mechanism explaining how SGLT2 inhibition may attenuate lean mass is somewhat 
elusive. One reason may be due to inhibition of SGLT2 proteins in the glucagon-secreting alpha-
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cells of the pancreatic islets. Therefore, SGLT2 inhibition increases glucagon secretion and 
endogenous (hepatic) glucose production (Bonner et al., 2015). The elevated hepatic glucose 
production might increase potential for glycogen storage in insulin sensitive adults, thus 
attenuating lean mass loss. Assuming Pill A is dapagliflozin, these data may have important 
implications for preserving lean mass, providing a greater reservoir for glucose storage and 
oxidation, and therefore maintenance of metabolic health, during caloric restriction. However, 
the liver is included in lean mass calculations. The increase in hepatic glucose production may, 
in theory, lower liver mass (lean mass). Thus, hepatic glucose production likely plays a limited 
role, if any, in attenuating lean mass loss.  Further research must investigate the mechanism 
behind SGLT2 inhibition mediated lean mass maintenance.  
The higher bone mineral content (BMC) following weight loss was unexpected. All 
current research points to the expectation that absolute BMC should decrease following weight 
loss. Additionally, weight loss is often accompanied by lower absolute BMC (Jensen et al. 2001; 
Taylor et al. 2015). For instance, canagliflozin, another SGLT2 inhibitor, is associated with 
decreased bone mineral content and increased fracture risk (Blevins et al. 2017). Hence the 
current finding is surprising. However, it is important to note that although this increase in BMC 
is statistically significant, the clinical/physiological significance of an increase of the reported 
magnitude may be questionable. Regardless, these results provide evidence that SGLT2 
inhibition via dapagliflozin is not associated with decreased bone health.  
RMR 
Resting metabolic rate often decreases with weight loss (Busetto et al., 1995; Byrne et al., 
2012; Fothergill et al., 2016; Johannsen et al., 2012). The influence of SGLT2 inhibition on 
energy expenditure is inconsistent across studies. Several investigations found SGLT2 inhibition 
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shifts macronutrient oxidation from carbohydrates to fat while maintaining energy expenditure in 
people with T2D despite the calories lost in urine (Abdul-Ghani et al., 2016; Kanazawa et al., 
2019). Other studies found a null effect in patients with T2D (Ferrannini et al., 2014) and a 
decrease in basal metabolic rate in obese and overweight women with Polycystic Ovary 
Syndrome (Javed et al., 2019). The current investigation discovered SGLT2 inhibition did not 
influence the dietary counseling induced decline in RMR. Lean mass heavily influences variation 
in RMR (Rolfe et al., 2017); therefore, we expected Pill B to have a larger decrease in RMR. 
Despite statistical significance, the magnitude of lean mass lost in participants supplemented 
with Pill B compared to Pill A may not overcome the large variability observed in RMR. This is 
supported in the current investigation by the lack of correlation between the magnitudes of 
change in lean mass and RMR, and a high ANCOVA p-value with RMR as the dependent 
variable and lean mass as the covariate. Another plausible reason for a decrease in RMR is lower 
sympathetic stimulation and/or decreased adrenergic receptor responsiveness (Bell et al., 2001; 
Straznicky et al., 2010). However, quantification of the sympatho-adrenal contribution to RMR 
is beyond the scope of the current investigation and consequently we are unable to address this 
potential mechanism directly. Overall, SGLT2 inhibition does not influence dietary counseling 
for weight loss induced decreases in RMR.  
Insulin Sensitivity 
Augmented glucosuria reduces fasting plasma glucose, improves glucose tolerance, and 
promotes calorie loss; leading to reduced glucose toxicity (decreased chronic hyperglycemia), 
weight loss, reduced lipotoxicity, improved β-cell function, and insulin sensitivity (Bonner et al., 
2015; Chen et al., 2013; González-Ortiz et al., 2018; Idris et al., 2009; Katsiki et al., 2010; 
Merovci et al., 2015; Tang et al., 2017). In opposition to previous discoveries, the current 
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investigation found no improvement in insulin sensitivity post dietary counseling, thus 
suggesting weight loss does not improve insulin sensitivity. However, the influence of SGLT2 
inhibition on insulin sensitivity was trending towards significance (P=0.055). Comparing 
average Matsuda scores, Pill A decreased slightly (Pre: 8.94 mU/L, Post: 8.61 mU/L), while Pill 
B increased (Pre: 6.27 mU/L, Post: 7.84 mU/L). Neither change was statistically significant 
(P=0.135). Potentially, a future study with larger sample sizes will find a significant drug 
interaction on insulin sensitivity. Based on the results of our literature search, this is the first 
study to find a null result on the influence of SGLT2 inhibition on insulin sensitivity in non-
exercising adults without diabetes undergoing dietary counseling. However, SGLT2 inhibition 
initiates glucagon secretion, stimulating endogenous hepatic glucose release (Bonner et al., 2015) 
and dampening the potential influence on insulin sensitivity (Newman et al. 2018). Metabolically 
healthy adults, such as those investigated in this study, adapt to increased endogenous hepatic 
glucose release by naturally increasing glucosuria, storage, and oxidation (Goodpaster et al., 
2017; Wilding, 2014), thus explaining the null effect SGLT2 inhibition has on circulating 
glucose and insulin sensitivity. It is likely SGLT2 inhibition has greater efficacy in patients with 
T2D than their healthy counterparts.  
Appetite and Satiety 
If the weight loss observed with SGLT2 inhibitors is less than hypothesized based on the 
glucosuria caloric loss, one would assume that SGLT2 inhibitors might increase hunger and 
appetite (Cefalu, 2014; Ferrannini et al., 2014; Zhang et al., 2014). It is likely that patients 
increase caloric intake rather than reduce energy expenditure when taking an SGLT2 inhibitor 
(Ferrannini et al., 2014). Data on whether SGLT2 inhibitors instigate increased appetite and 
caloric consumption are inconclusive. SGLT2 inhibition does not appear to influence energy 
43 
 
intake (Bertran et al., 2018). The current investigation found no significant changes in appetite 
and satiety other than lower subjective feeling of “fullness” 60 minutes post meal primer as 
evidenced by lower scores in question 3 of satiety surveys. Although statistically significant, the 
improved satiety is likely not clinically significant. Despite lower hunger scores, participants had 
the same total energy intake pre and post counseling. Therefore, this investigation supports 
previous evidence indicating SGLT2 inhibition does not influence appetite.    
Limitations: 
There are several limitations in the current investigation. We chose to focus on minimally 
active overweight and obese adults, without any diagnosed metabolic disorders. Although free 
from diabetes, this population is at risk for developing insulin resistance because of a mostly 
sedentary lifestyle and poor body composition. Our rationale for choosing this population allows 
investigation into the potential interaction between weight loss and SGLT2 inhibition without 
complications associated with metabolic dysfunction such as insulin resistance, improper fatty 
acid oxidation, and intramyocellular lipid accumulation (Andrews et al., 2011; Goodpaster et al., 
2017; Kelley et al., 1999; Sitnick et al., 2009). Although it is reasonable to question the 
effectiveness/relevance of SGLT2 inhibition in a metabolically healthy adult free, at least two 
independent studies have investigated dapagliflozin (10 mg/day) induced SGLT2 inhibition in 
healthy, diabetes-free adults (Komoroski et al., 2009; Yang et al., 2013). Furthermore, numerous 
pharmacotherapy protocols studied healthy, disease-free populations (Bahls et al., 2017; Braun et 
al., 2008; Carlson, Tou, Parikh, Birmingham, & Butler, 2011; Duff et al., 2017; Kohrt et al., 
2010; Ring et al., 2013; Scalzo et al., 2014), including the Diabetes Primary Prevention Trial 
(Knowler et al., 2002), in which the efficacy of metformin was investigated in adults without 
diabetes. Thus, we remain convinced with the rationale for our protocol.  
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Another limitation of our study was the use of ‘free-living participants and therefore lack 
of control over participants’ energy intakes. We did not supply calorie-reduced meals to 
participants; participants were free to cook and eat as they pleased. The rationale for our 
approach was based on maximizing ecological validity. We recognize that this approach may 
introduce potential bias and/or variability in our data, thus lowering the chance of finding 
statistical significance. However we do not believe it influenced our outcomes and/or 
interpretation of data because this bias was likely randomly distributed and not systematic. Also, 
while the average weight loss experienced by the study participants was only 3-4 kg, we 
intentionally chose to focus on modest weight reduction for the following reason.  If SGLT2 
inhibition alone were to produce a small decrease in body weight, this effect could be totally lost 
with large decreases in body weight induced by a severely energy-restricted, very-low calorie 
diet.  Based on our findings, there is little evidence to indicate that SGLT2 inhibition contributes 
to a greater magnitude of the energy deficit when accompanied by 12 weeks of weight loss 
counseling compared to counseling alone.   
Incorporating two more groups: 1). Placebo with no dietary counseling and 2). 
dapagliflozin with no dietary counseling could allow for further differentiation between 
dapagliflozin and counseling. However, the time and financial constraints did not make this 
feasible.  
We decided to study glucose regulation using the oral glucose tolerance test instead of the 
insulin sensitivity via the gold-standard hyperinsulineimic euglycemic clamp technique. Our 







 Dietary counseling significantly influences body composition in overweight/obese adults 
free of metabolic disorder. Twelve weeks of dietary counseling favorably modified body mass, 
fat mass, heart rate, and insulin sensitivity. The novel observation of the current study is SGLT2 
inhibition neither augmented nor attenuated these beneficial physiological outcomes; however, 
Pill B exacerbated the loss of lean mass (muscle mass). These data may have important 
implications in the modification of lean mass, and therefore maintenance of metabolic health, 
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